NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/30/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization284.73 mln
Float46.69 mln
Earnings Date07/30/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.55
Likely reliable
1-Year Forecast
7.60
Transformational upside
Relative Strength
25
/ 100
Underperforming
Debt / Equity
1.44
Elevated leverage
ROE
-74.76
Deeply negative
Business Description
Founded in Paris in 1999, Cellectis is a clinical-stage company working to treat cancer and other serious diseases by modifying the genetic makeup of immune cells. Its main focus is on developing off-the-shelf T-cell therapies that can be given to any patient without the need for personalized manufacturing. The company currently has several treatments in clinical testing, targeting blood cancers such as certain types of leukemia and lymphoma, as well as solid tumors including kidney cancer and melanoma.
